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Abstract An ATP-dependent chromatin remodeling factor,
SNF/SWI complex, acts as a coactivator for numerous
transcriptional factors. One of the best-documented examples
is nuclear receptors, although the molecular mechanism for this
coactivation has not been sufficiently elucidated. Here we show
that hbrm/hSNF2K and BRG-1/hSNF2L, the ATPase subunits
of the human SNF/SWI complexes, specifically associate in vitro
and in vivo with TATA element modulatory factor (TMF)/
ARA160, which has been described as a binding protein to and
coactivator for the androgen receptor. This interaction requires
highly conserved N-terminal regions of hbrm/hSNF2K and BRG-
1/hSNF2L and a C-terminal region of TMF/ARA160. Immuno-
fluorescence and Western blot studies revealed that the TMF
isoforms differentially localize in the Golgi apparatus and the
nucleus. 2 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
The SNF/SWI proteins have been genetically identi¢ed as
gene-speci¢c transcriptional factors ([1^3], reviewed in [4^5]).
The subunits are highly conserved in eukaryotes, from yeast
to mammals, ([1^3,6^17], reviewed in [18,19]) and have been
found to form multisubunit complexes [20^24]. These com-
plexes remodel the chromatin of target genes in an ATP-de-
pendent manner [20,25] through interaction with transcription
factors and thereby facilitate the following processes (e.g. fac-
tor assembly) of transcriptional initiation [26,27]. It has been
shown that the SNF/SWI components interact directly with
various types of transcription factors: Rb [28], EKLF [29],
c-myc [30], AP1 [31] and mSin3A [32], as well as nuclear re-
ceptors [33], which are best characterized. Transcriptional ac-
tivation by the glucocorticoid receptor (GR) and the estrogen
receptor (ER) is enhanced by ectopic expression of ATPase
subunits of the SNF/SWI complexes: hbrm/hSNF2K and
BRG-1/hSNF2L [6^8] (for simplicity, mostly referred to here-
after as hSNF2K and hSNF2L). Nucleosome remodeling and
activation of cell-free transcription of a chromatin template by
the SNF/SWI complexes are enhanced by GR in a binding
element-dependent manner [34,35]. There are reports that nu-
clear receptors directly interact with the SNF/SWI subunits in
a ligand-enhanced manner: GR directly interacts with SNF2/
SWI2 [36] and BAF250/p250 (one of the largest subunits of
human SNF/SWI complexes) [14]; ER also directly interacts
with hbrm/hSNF2K [37]. It is not clear, however, whether
these direct interactions are determinants of in vivo activation
and common to other nuclear receptors. Thus mechanisms by
which the SNF/SWI complexes or components act to enhance
nuclear receptor-dependent transcriptional activation still re-
main to be su⁄ciently understood.
In an e¡ort to identify proteins that interact with hSNF2K
and hSNF2L, we used the yeast two-hybrid screening method
and isolated a cDNA whose product was originally isolated as
an HIV-1 TATA element modulatory factor (TMF) [38] and
has also been characterized as a coactivator (ARA160) for the
androgen receptor (AR) [39]. We showed that this protein
(TMF/ARA160, referred to as TMF in most cases) speci¢cally
interacts with hSNF2K/L as well as with the SNF/SWI com-
plexes, both in vitro and in vivo, and that short and mutually
identically positioned N-terminal regions of hSNF2K and
hSNF2L as well as a C-terminal region of TMF are su⁄cient
for the interaction. We also showed that TMF localizes in the
Golgi apparatus at high density and that the 120 kDa form of
TMF is also present in the nucleus, which may lead to the
¢nding of new events regulating the SNF/SWI complexes.
2. Materials and methods
2.1. Yeast two-hybrid screening and assays
Plasmids pGBT9 and pGADGH (Clontech) were used to express
the bait and prey proteins, respectively. A cDNA fragment encoding
an N-terminal 1243 amino-acid portion of hSNF2L was inserted into
pGBT9 to express a fusion protein with the Gal4 DNA binding do-
main (GAL4BD). This plasmid was used as bait to screen a HeLa
cDNA-pGADGH library (Clontech) in the HF7c yeast indicator cells.
Clones positive for the Hisþ phenotype were selected in the presence
of 5 mM 3-aminotriazole and then assayed for L-galactosidase activity
as described [40]. Interaction was also quantitated with indicator
strains, SFY526 (Clontech) and Y187 [41] (kindly provided by S.
Elledge, Baylor College of Medicine).
2.2. Protein preparations
Fusion proteins with glutathione S-transferase (GST) were ex-
pressed by employing pGEX5x (Amersham-Pharmacia) in an Esche-
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richia coli strain BL21(DE3)LysS (Novagen). For in vitro transcrip-
tion^translation, template RNAs were prepared by transcription of
pBluescript SK derivatives containing an hSNF2K or hSNF2L
cDNA fragment (truncated with BglII or BamHI, respectively) with
T7 RNA polymerase in the presence of mGpppG and labeled protein
was synthesized with rabbit reticulocyte lysate (Promega) in the pres-
ence of [35S]methionine. For size fractionation, the HeLa nuclear ex-
tract [42] was fractionated stepwise on DEAE^Sepharose (Amersham-
Pharmacia) with 0.5 M KCl after a 0.1 M KCl wash in column bu¡er
(20 mM Tris^HCl, pH 7.5, 5% glycerol, 1 mM EDTA, 1 mM DTT,
0.1 mM PMSF and 0.05% NP-40) and then further fractionated on a
molecular sieving agarose matrix Bio Gel A-5m (Bio-Rad) in column
bu¡er containing 200 mM KCl. To prepare cytoplasmic and nuclear
fractions of RL95-2, cell pellet was suspended in the hypotonic lysis
bu¡er (20 mM Tris^HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 1 mM
PMSF and 0.5% NP-40). After centrifugation in microtube for 5 min
at 5 000 rpm, the supernatant was isolated as cytoplasmic fraction and
the nuclear pellet was additionally treated with the lysis bu¡er once or
twice. The resulting nuclear pellets as well as the cytoplasm were
directly suspended in sodium dodecyl sulfate (SDS) sample bu¡er,
sonicated and separated by SDS^polyacrylamide gel electrophoresis
(SDS^PAGE).
2.3. Pull-down assays
Pull-down assay with GST fusion proteins was performed as de-
scribed [15]. Brie£y, an E. coli extract containing an expressed re-
combinant protein was incubated with glutathione^Sepharose (Amer-
sham-Pharmacia), washed extensively and used for the binding
reaction with 35S-labeled protein or HeLa nuclear extract. After being
washed with a bu¡er containing 0.3 M NaCl, bound fractions were
directly heated for 5 min at 95‡C in SDS sample bu¡er and separated
by (SDS^PAGE). Gels were either analyzed by autoradiography after
treatment with the £uorography reagent (Amplify, Amersham-Phar-
macia) or processed by Western blotting analysis.
2.4. Two-hybrid assay in mammalian cells
The GAL4BD-hSNF2 plasmids were constructed by inserting the
full-length hSNF2K or hSNF2L cDNA into pECE, yielding pECE-
hSNF2K or pECE-hSNF2L [43]. The VP16-TMF plasmid was con-
structed by inserting both the VP16 activation domain sequence and a
TMF C-terminal cDNA fragment (amino acids (aa) 699^1093) into
the pSV vector (designated pSVVP16-TMFC) [8]. The plasmids were
transfected by the standard calcium phosphate coprecipitation method
with the reporter plasmid G6(3119)HIVLTRvTAR [43] in Cos-1
cells, and the interaction activity was measured by a standard CAT
assay with 14C-chloramphenicol (Amersham-Pharmacia) and by silica
gel thin layer chromatography.
2.5. Antibody preparations and Western blot analyses
Rabbit antisera were raised against hSNF2K (aa 1374^1484) or
TMF (aa 831^1093) recombinant protein containing a histidine-tag.
The anti-hSNF2K antiserum (N3C2) recognizes both hSNF2K and
hSNF2L proteins in Western blotting. For immunostaining, antisera
were a⁄nity puri¢ed with antigen-conjugated Sepharose as described
[15]. A monoclonal antibody against the 58 kDa Golgi protein was
purchased (clone 58K-9, Sigma). Western blotting was carried out
under standard conditions with Hybond-ECL membranes and ECL
detection reagents (Amersham-Pharmacia).
2.6. Cell culture, transfection, immuno£uorescence and green
£uorescent protein (GFP)-fusion protein localization assays
HeLa, Cos-1 and endometrial carcinoma RL95-2 cells were cultured
in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
bovine serum. HeLa cells were synchronized at G2-M phase by treat-
ing them with 2.5 mM thymidine (at 0 h), released from the thymidine
block at 24 h, further treated with 0.1 Wg/ml nocodazole (Sigma) at 36
h and used at 48 h. For immuno£uorescence analysis, cells were ¢xed
with 3.7% paraformaldehyde/phosphate-bu¡ered saline (PBS) and
permeabilized with 1% Triton X-100/PBS. After washing with PBS,
the cells were incubated with a⁄nity-puri¢ed antibody and then with
FITC-conjugated anti-rabbit IgG antibody. For the GFP analysis, the
cells were transfected with a pEGFP-C1 derivative plasmid containing
the full-length TMF cDNA, ¢xed with 3.7% paraformaldehyde/PBS
at 48 h after transfection, washed with PBS, and examined with a
£uorescent microscope.
3. Results
3.1. TMF/ARA160 is an hSNF2-binding protein
To identify hSNF2-binding proteins, we have used a yeast
two-hybrid screening method with an N-terminal aa region of
the hSNF2L protein [8] as bait and a HeLa cDNA library as
prey. From a total of 106 cDNAs in the library, one of the
primary positive clones exhibited high L-galactosidase activ-
ities in combination with a prey plasmid expressing hSNF2K
or hSNF2L but not with any of several negative control prey
plasmids. This cDNA encodes a C-terminal region (395 aa) of
a protein that has been reported as a speci¢c DNA-binding
protein of the HIV-1 TATA element (TMF) [38] and also as a
cofactor protein of AR (ARA160) [39] (Fig. 1). This protein
attracted our interest, because the SNF/SWI complexes have
been implicated in nuclear receptor-dependent transcriptional
activation.
To further investigate this interaction, we performed two
experiments: a pull-down assay with in vitro translated pro-
teins and a mammalian two-hybrid assay. In vitro translated
35S-labeled hSNF2K and hSNF2L proteins (N-terminal 633
and 837 aa, respectively) were tested for their interaction
with GST-fused TMF bound on Sepharose resin. As a result,
GST-TMF but not GST alone e⁄ciently trapped these pro-
teins (Fig. 2A). We next tested the interactions of these two
proteins by a mammalian two-hybrid assay in which tran-
scription activity of the reporter plasmid was measured by a
CAT assay. Transcription activities were strongly enhanced
with the combinations of GAL4BD-hSNF2K or GAL4BD-
hSNF2L and VP16-TMF but not with each partner alone
(Fig. 2B), indicating that the interaction clearly occurred
with speci¢city in vivo in yeast.
3.2. TMF associates with human SNF/SWI complexes in vitro
and in vivo
The hSNF2K and hSNF2L proteins are components of mul-
tiprotein complexes with di¡erent compositions and also in-
teract with numerous factors [15,28^32]. It is therefore possi-
ble that some of other SNF/SWI subunits or interacting
proteins sterically exclude the interaction. To study the inter-
action between TMF and the SNF/SWI complexes, a pull-
down assay with GST-fusion proteins and HeLa nuclear ex-
tract was carried out. GST-TMF, but neither GST nor GST-
USF, e⁄ciently bound the hSNF2 proteins (Fig. 3A). We next
analyzed the chromatographic behavior of native TMF with a
gel ¢ltration column. Previously, the SNF/SWI complexes
were reported to be fractionated at an approximate molecular
mass of 2 MDa [7] ; this ¢nding appears to be reproduced in
this study (Fig. 3B). A Western blot analysis of the chromato-
Fig. 1. Isolation of an hSNF2L (BRG-1)-binding protein by yeast
two-hybrid screening. A cDNA encoding a protein that interacts
with the amino-terminal region (1^1243 aa) of hSNF2L was isolated
from the 106 cDNA clones of a HeLa cDNA expression library and
identi¢ed as a C-terminal region (aa residues 699^1093, indicated by
an arrow) of TMF/ARA160. The domain structure of TMF/
ARA160 is shown.
FEBS 26139 27-5-02
K. Mori, H. Kato/FEBS Letters 520 (2002) 127^132128
graphic fractions with anti-hSNF2K/L and anti-TMF antisera
revealed that hSNF2K/L and TMF were exactly cofractio-
nated at the same position of an approximate molecular
mass of 1^2 MDa (Fig. 3B). A lesser fraction of TMF mi-
grated at an isolated position of a lower molecular mass (ap-
proximately 600 kDa). This result indicates that most (appar-
ently more than 50%) of the TMF protein associates with (at
least certain forms of) the SNF/SWI complexes in the nuclear
extract, albeit TMF is not a stoichiometric component.
3.3. An N-terminal domain of hSNF2K and hSNF2L, and
a C-terminal domain of TMF are required for the
interaction
To determine which regions are required for the interaction
by the yeast two-hybrid assay, a set of deletion mutants were
constructed for hSNF2K, hSNF2L, and TMF. Interaction was
tested in the yeast indicator strains SFY526 and Y187 with
combinational transformation of one of the full-length con-
structs and one of the deletion constructs of the partner pro-
teins. Consequently, short interaction regions have been iden-
ti¢ed: the N-terminal regions of hSNF2K (aa 338^585) and
hSNF2L (aa 359^601) as well as a C-terminal region of TMF
(aa 835^1093) (Fig. 4A,B). The regions of hSNF2K and
hSNF2L locate in an identical position (almost completely
overlapped in homology alignment) and have high identity
(87.6%) with each other, suggesting that the regions have a
very similar interaction domain. The interaction domain of
TMF contains a potential leucine zipper [38].
3.4. Subcellular localization of TMF
Localization and activities of the SNF/SWI complexes and
their components are dynamic. For example, hbrm/hSNF2K
and BRG-1/hSNF2L are phosphorylated and excluded from
the condensed chromosome during mitosis [44] coincident
with the inactivation of the remodeling activity [45]. The
BAF complex (SNF/SWI complexes) also becomes associated
with chromatin and the nuclear matrix by PIP2 treatment [16].
We therefore investigated the subcellular localization of TMF
in HeLa cells by immuno£uorescence analysis with an a⁄nity-
puri¢ed anti-TMF antibody. Unexpectedly, we found that it
was mainly localized in the Golgi apparatus (Fig. 5A). This
pattern is identical to that seen with anti-mannosidase II anti-
serum (kindly provided by Dr. K. Moremen, University of
Georgia; data not shown), which is a typical Golgi-localizing
protein [46]. In HeLa cells treated with nocodazole after a
thymidine block (i.e. synchronized in G2-M phase), £uores-
cence was observed in the fragmented bodies of the Golgi
apparatus (Fig. 5B,C). At these stages, nuclei appear to be
more densely stained than they are in interphase, whereas
the nucleoli are excluded from staining.
To con¢rm the TMF localization, we utilized an EGFP
(enhanced GFP) fusion strategy. When pEGFP-TMF was
transfected into Cos-1 cells, the £uorescence was again de-
tected in the Golgi apparatus with moderate staining of the
cytoplasm (Fig. 5D). This higher background could be due to
proteolysis of EGFP-TMF with no Golgi-localization signal
or to mislocalization of the overexpressed protein, which was
shown for a Golgi-localizing protein, phospholipase D [47].
To further investigate whether TMF is present in the nu-
cleus, cytoplasmic and nuclear fractions of RL95^2 cells were
prepared by a hypotonic-NP40 lysis method and analyzed by
Western blotting. As a result, a substantial amount (estimated
as 20^30%) of a shorter form (120 kDa), but not the full
length form (160 kDa), of TMF was detected in the fractions
from the extensively washed nuclei (Fig. 5E, upper panel). In
contrast, a control 58 kDa Golgi protein (48) was exclusively
detected in the cytoplasmic fraction (Fig. 5E, lower panel). It
is thus likely that at least signi¢cant amount of the 120 kDa
TMF protein is indeed present in the nucleus.
Fig. 2. Interaction between hSNF2K/L and TMF in vivo and in vi-
tro. A: Pull-down assay. In vitro translated [35S]-labeled hSNF2K
and hSNF2L proteins were incubated with glutathione^Sepharose
bearing GST or GST-TMF and washed with a bu¡er containing 0.3
M NaCl. The bound fraction as well as the same amount of each
input was separated by SDS^PAGE and analyzed by £uorography.
The hSNF2K and hSNF2L bands, indicated by an arrow and arrow-
head, appear somewhat larger than their respective theoretical mo-
lecular masses of 70 and 94 kDa. B: Mammalian two-hybrid inter-
action assay. A plasmid (8.0 Wg) expressing GAL4BD-hSNF2K or
GAL4BD-hSNF2L was transfected with pSVVP16-TMF (4.0 Wg) in
the presence of a reporter plasmid G6(3119)HIVLTRvTAR (2.0
Wg) as denoted. Acetylated forms of [14C]chloramphenicol are indi-
cated by arrows. The same amounts of plain vector plasmids were
included in the blank (3) transfection samples.
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4. Discussion
A number of coactivators for nuclear receptors, which in-
clude the SNF/SWI complexes, have been reported and their
actions are likely to involve multiple steps that depend on
cooperative physical interactions (reviewed in [49^51]). We
have searched for factors that interact with hbrm/hSNF2K
and/or BRG-1/hSNF2L and, consequently, have identi¢ed
TMF/ARA160 by yeast two-hybrid screening. TMF/
ARA160 has been reported as a putative coactivator for
AR. It was observed to bind to AR in a ligand (DHT)-depen-
dent manner in vitro (by pull-down assay) and in vivo (by
mammalian two-hybrid assay). Furthermore, its enhancement
of transcription from the MMTV promoter-driven reporter is
dependent on AR, GR, or PR (progesterone receptor) and
their cognate ligand. Molecular mechanisms that control the
actions of this putative coactivator, however, have not been
elucidated.
Fig. 3. Association of TMF with human SNF/SWI complexes. A: pull-down assay. HeLa nuclear extract (NE) was incubated with GST, GST-
USF, or GST-TMF. After washing, the bound fractions were analyzed by 5% PAGE and Western blotting with anti-hSNF2 antiserum. A 190
kDa hSNF2K/L band is indicated by an arrow. B: Cofractionation of TMF with human SNF/SWI complexes. A 0.3 M KCl DEAE^Sepharose
eluate was fractionated by gel ¢ltration chromatography. Fractions 2^30 were analyzed as for (A) with a mixture of anti-hSNF2K/L and anti-
TMF antisera. Western blotting patterns for HeLa NE with anti-hSNF2, anti-TMF, or their mixture, are included in the left three lanes. Spe-
ci¢c bands are indicated by arrows. The peak positions of 669 and 443 kDa marker proteins are fractions 19 and 27, respectively.
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We believe that the interaction between hSNF2K/L and
TMF is physiologically relevant for several reasons. First,
TMF associates not only with the hbrm/hSNF2K and BRG-
1/hSNF2L proteins but also with the SNF/SWI complexes in
vitro and in vivo; second, the binding activities we obtained
seem to be su⁄ciently strong; third, the regions of hSNF2K/L
required for the interaction mapped to an identical position
with a mutually high identity (87.6%); and fourth, a substan-
tial amount of TMF was detected in the nuclear fractions. An
important question would be raised as to whether only some
special forms of the SNF/SWI complexes (or the PBAF com-
plex) or their derivatives containing interacting factors can
associate with TMF. This remains to be addressed. Although
it is possible that TMF was solubilized from the Golgi appa-
ratus and contaminated during the nuclear extract prepara-
tion, we believe from our immuno£uorescence study that at
least some fraction of TMF is present in the nucleus especially
during mitotic phase. Thus, on the premise that TMF-
(ARA160) is a coactivator for nuclear receptors such as
AR, it is tempting to suppose that TMF mediates actions of
the SNF/SWI complexes on the nuclear receptors and partic-
ipates in the sequential and highly cooperative actions of the
numerous nuclear-receptor coactivators [52]. Alternatively,
TMF could confer totally di¡erent functions on the SNF/
SWI complexes. The limited information so far available on
TMF has precluded us from speculating on other possibilities
at present.
Unique observations are that TMF localizes in the Golgi
apparatus and only the shorter (presumable processed) form
of TMF is also present in the nucleus. There are several prece-
Fig. 4. Interaction regions of hSNF2K/L and TMF. Regions re-
quired for the interaction were determined by the yeast two-hybrid
assay with sets of deletion constructs. Interaction activities were
measured by L-galactosidase assays (3, negative; +, positive; ++,
strongly positive). Interaction regions of hSNF2K and hSNF2L (A),
and TMF (B) are shown. Minimal regions reside in aa residues
338^585 of hSNF2K, 359^601 of hSNF2L and 835^1093 of TMF.
The glutamine-rich and glycine/proline-rich regions (black), ATPase
motifs (light gray), and charged regions (dark gray) are depicted.
Fig. 5. Immuno£uorescence analysis of TMF protein. HeLa cells were either asynchronized (A) or synchronized by treatment with nocodazole
after releasing them from thymidine block (B and C). Cells were ¢xed and permeabilized as described in Section 2 and incubated with a⁄nity-
puri¢ed anti-TMF/ARA160 antibody and then with FITC-conjugated anti-rabbit IgG antibody. FITC immuno£uorescence images of the Golgi
apparatus show that fragmentation in (C) is further advanced than that in (B). D: Cos-1 cells were transfected with the pEGFP-TMF plasmid
and EGFP £uorescence is shown. E: Cytoplasmic (lane 1) and nuclear fractions (lanes 2 and 3) of RL95-2 cells were analyzed by Western blot-
ting with anti-TMF antiserum (upper panel) and monoclonal antibody to the Golgi 58 kDa protein [48] (lower panel). Nuclear extracts were
prepared from nuclei washed two (lane 2) or three times (lane 3). The arrows indicate speci¢c bands.
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dents, such as for phospholipase D1 and cyclin B2 [47,53], for
proteins that exhibit dual localization in the Golgi apparatus
and nucleus. The nuclear localization of TMF appears to be
enhanced in the G2-M phase (Fig. 5B,C), suggesting that
TMF has a preference for being present in the nucleus, unless
otherwise trapped. In this context it is quite interesting to note
that PLD1 is dissociated from the Golgi apparatus upon stim-
ulation with 1-BtOH, which diminishes PIP2 synthesis, possi-
bly because PLD1-binding to the Golgi membrane is weak-
ened [47]. We therefore imagine that TMF may be
translocated as a result of biological changes or stimulations;
this possibility is currently being investigated.
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